There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
Results for performance period 4 of the Oncology Care Model just came out; what are the initial takeaways?
Practices that consistently have performed well continued to perform well. Practices that were trending in the right direction, but maybe haven’t made savings, a few of our practices have made savings, they made it over that finish line, and we’ve set that expectation that that is likely to happen given the good work that they were doing, and they’re seeing those results. And practices that haven’t performed well consistently, no surprise, didn’t get a very good report card with this reconciliation.
About half of our practices earned a PBP [performance-based payment] by this period, which is a performance period 4. That’s an increase in what we saw since performance period 3, which was about a third of our customer base earned a savings payment.
So, that was exciting news. I think overall, practices are happy with the results. I’m seeing a lot of smiling faces based on those results here, at [the Quality Cancer Care Alliance Fall 2019 Leadership Summit], which is great. But they’re a high-performing group, so they’re biased in that way, as they’re more progressive and stronger performing than some of the other practices that we work with. But good results overall, I think.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
May 17th 2025The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Read More
Specialty Drug Users to Gain Relief Under Medicare Reforms
May 16th 2025A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.
Read More